{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:27:40Z","timestamp":1772821660729,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.004","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"371-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Third-Generation Tyrosine Kinase Inhibitors and Beyond"],"prefix":"10.1053","volume":"47","author":[{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.004_bib1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib2","first-page":"114","article-title":"International Randomized Study of Interferon Vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib3","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib7","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib8","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)","volume":"62","author":"Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","article-title":"Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL","volume":"112","author":"Azam","year":"2003","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib11","first-page":"110","article-title":"Mutational analysis of chronic myeloid leukemia (CML) clones reveals heightened BCR-ABL1 genetic instability and wild-type BCR-ABL1 exhaustion in patients failing sequential imatinib and dasatinib therapy","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib14","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib15","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib16","doi-asserted-by":"crossref","first-page":"11011","DOI":"10.1073\/pnas.0504952102","article-title":"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases","volume":"102","author":"Carter","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib18","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib20","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib21","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib22","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib23","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib24","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","article-title":"AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL","volume":"94","author":"Weisberg","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib25","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib27","first-page":"112","article-title":"Stem cell transplant (SCT) for patients (pts) with chronic myeloid leukemia (CML) resistant to tyrosine kinase inhibitors (TKI) with BCR-ABL kinase domain (KD) mutation T315I","author":"Velev","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib28","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib29","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib31","first-page":"112","article-title":"Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study","author":"Giles","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib32","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib33","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib34","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1021\/jm900166t","article-title":"9-(Arenethenyl)purines as dual Src\/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation","volume":"52","author":"Huang","year":"2009","journal-title":"J Med Chem"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib35","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib37","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Carpinelli","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib38","article-title":"Danusertib hydrochloride (PHA-739358), a multi-kinase Aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib39","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358","volume":"67","author":"Modugno","year":"2007","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib40","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.1030.1030","article-title":"PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL","volume":"110","author":"Paquette","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.3232.3232","article-title":"Preliminary clinical activity in a phase I trial of the BCR-ABL\/IGF-1R\/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation","volume":"112","author":"Cortes","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.576.576","article-title":"Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I","volume":"112","author":"Van Etten","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","article-title":"Allosteric inhibitors of Bcr-abl-dependent cell proliferation","volume":"2","author":"Adrian","year":"2006","journal-title":"Nat Chem Biol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib44","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib45","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1073\/pnas.0800587105","article-title":"SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib","volume":"105","author":"O'Hare","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib46","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood.V86.9.3322.bloodjournal8693322","article-title":"Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase","volume":"86","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib47","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1182\/blood.V93.12.4149","article-title":"Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia","volume":"93","author":"O'Brien","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/cncr.22398","article-title":"Phase I\/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib49","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1158\/0008-5472.CAN-06-1216","article-title":"A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia","volume":"66","author":"Chen","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib50","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia patients who harbor the Bcr-Abl T315I mutation\u2014results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib51","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors\u2014results of a multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ccr.2007.10.015","article-title":"Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease","volume":"12","author":"Thomas","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib53","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib54","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2006-10-054098","article-title":"Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells","volume":"110","author":"Peng","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib55","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib56","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.leu.2403724","article-title":"Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli","volume":"19","author":"Holtz","year":"2005","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib57","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib59","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1158\/1078-0432.CCR-06-1736","article-title":"The hedgehog signaling pathway in cancer","volume":"12","author":"Evangelista","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib60","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1242\/dev.129.2.361","article-title":"Hedgehog is required for murine yolk sac angiogenesis","volume":"129","author":"Byrd","year":"2002","journal-title":"Development"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib61","doi-asserted-by":"crossref","first-page":"14134","DOI":"10.1073\/pnas.0604568103","article-title":"Hedgehog modulates cell cycle regulators in stem cells to control hematopoietic regeneration","volume":"103","author":"Trowbridge","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib62","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2008.08.003","article-title":"Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation","volume":"14","author":"Dierks","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib63","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/(SICI)1096-8652(199701)54:1<61::AID-AJH9>3.0.CO;2-2","article-title":"Chronic myeloid leukemia as an immunological target","volume":"54","author":"Lim","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib65","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr-abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib66","first-page":"237","article-title":"Interferon-alpha: mechanisms of action in chronic myelogenous leukemia in chronic phase","volume":"40","author":"Guilhot","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0037-1963(03)70043-2","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"40","author":"Barrett","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib68","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/79526","article-title":"Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia","volume":"6","author":"Molldrem","year":"2000","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib69","doi-asserted-by":"crossref","first-page":"77a","DOI":"10.1182\/blood.V104.11.259.259","article-title":"Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia","volume":"104","author":"Qazilbash","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib70","article-title":"Randomized phase II study of proteinase 3-derived PR1 peptide vaccine and GM-CSF with or without PEG-interferon alfa-2B to eradicate minimal residual disease in chronic myeloid leukemia","volume":"112","author":"Quint\u00e1s-Cardama","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib71","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib72","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib73","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.648.648","article-title":"BCR-ABL derived peptide vaccine in chronic myeloid leukemia patients with molecular minimal residual disease during imatinib: interim analysis of a phase 2 multicenter GIMEMA CML Working Party trial","volume":"114","author":"Bocchia","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib74","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.903.903","article-title":"Pilot study of a Wilms tumor protein (WT1) heteroclitic peptide vaccine in patients with myeloid and thoracic neoplasms","volume":"110","author":"Maslak","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib76","article-title":"K562\/GM-CSF vaccination reduces tumor burden, including achieving molecular remissions, in chronic myeloid leukemia (CML) in patients (Pts) with residual disease on imatinib mesylate (IM)","volume":"24","author":"Smith","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.004_bib77","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:16Z","timestamp":1758522076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0037196310000788"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Third-Generation Tyrosine Kinase Inhibitors and Beyond","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}